FR11C0030I1 - - Google Patents

Info

Publication number
FR11C0030I1
FR11C0030I1 FR11C0030C FR11C0030I1 FR 11C0030 I1 FR11C0030 I1 FR 11C0030I1 FR 11C0030 C FR11C0030 C FR 11C0030C FR 11C0030 I1 FR11C0030 I1 FR 11C0030I1
Authority
FR
France
Prior art keywords
formulation
aztreonam
treatment
pseudomonas aeruginosa
caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980480&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0030(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR11C0030I1 publication Critical patent/FR11C0030I1/fr
Application granted granted Critical
Publication of FR11C0030I2 publication Critical patent/FR11C0030I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR11C0030C 2000-12-27 2011-08-16 Aztreonam inhalable destine au traitement et a la prevention d'infections bacteriennes pulmonaires Active FR11C0030I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25842300P 2000-12-27 2000-12-27
PCT/US2001/050062 WO2002051356A2 (en) 2000-12-27 2001-12-20 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (2)

Publication Number Publication Date
FR11C0030I1 true FR11C0030I1 (de) 2011-09-23
FR11C0030I2 FR11C0030I2 (fr) 2012-03-16

Family

ID=22980480

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0030C Active FR11C0030I2 (fr) 2000-12-27 2011-08-16 Aztreonam inhalable destine au traitement et a la prevention d'infections bacteriennes pulmonaires

Country Status (19)

Country Link
US (6) US6660249B2 (de)
EP (2) EP2301524B1 (de)
JP (1) JP4646489B2 (de)
AT (1) ATE502623T1 (de)
AU (1) AU2002231244B2 (de)
BE (1) BE2011C029I2 (de)
BR (1) BRPI0116757B8 (de)
CA (2) CA2433280C (de)
CY (2) CY1111571T1 (de)
DE (2) DE60144291D1 (de)
DK (2) DK2301524T3 (de)
ES (2) ES2406405T3 (de)
FR (1) FR11C0030I2 (de)
IL (3) IL156596A0 (de)
LU (1) LU91851I2 (de)
NL (1) NL300492I2 (de)
NO (3) NO329643B1 (de)
PT (2) PT1353647E (de)
WO (1) WO2002051356A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2002231244B2 (en) * 2000-12-27 2006-06-29 Gilead Sciences, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US20030133925A1 (en) * 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
CA2477979A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
KR100687001B1 (ko) 2002-08-05 2007-02-27 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 아즈트레오남의 제법
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
CA2522158C (en) * 2003-04-14 2018-03-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
CA2526362C (en) * 2003-05-20 2012-10-09 James F. Collins Ophthalmic drug delivery system
ES2304078B2 (es) * 2003-07-02 2009-09-16 Gilead Sciences Inc. Sal de aztreonam-l-lisina y metodos para la preparacion de la misma.
AU2004257632C1 (en) * 2003-07-03 2010-04-15 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
MX2007000526A (es) 2005-05-09 2007-03-28 Sicor Inc Proceso para elaborar aztreonam.
WO2008039987A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Methods of treating pulmonary distress
HUP0700007A2 (en) * 2007-01-08 2008-10-28 Asthma Rehabilitacios Ct Kft Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
CN101951906A (zh) * 2007-10-01 2011-01-19 吉里德科学公司 用于治疗肺病中的健康相关生命质量缺陷的吸入式氨曲南赖氨酸
CN101939030B (zh) * 2007-11-27 2014-09-03 阿尔吉法玛公司 藻酸盐低聚物在抗击生物膜中的用途
EP2098219A1 (de) 2008-03-05 2009-09-09 PARI Pharma GmbH Makrolidzusammensetzungen mit verbessertem Geschmack und verbesserter Stabilität
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
KR101639098B1 (ko) 2009-03-26 2016-07-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 폐 질환 치료용 건조 분말 제형 및 방법
SI2437783T1 (sl) 2009-06-03 2014-04-30 Algipharma As Obdelava bakterije acinetobacter z alginatnimi oligomeri in antibiotiki
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
MX354828B (es) 2010-09-29 2018-03-22 Pulmatrix Operating Co Inc Polvos secos de cationes metálicos monovalentes para inhalación.
DK3470057T3 (da) 2010-09-29 2021-11-22 Pulmatrix Operating Co Inc Kationiske tørpulvere omfattende magnesiumsalt
EP2804589A1 (de) * 2012-01-16 2014-11-26 Mahmut Bilgic Pharmazeutische formulierungen mit aztreonam
AU2013225982B2 (en) 2012-02-29 2017-11-30 Pulmatrix, Inc. Inhalable dry powders
AU2013384270A1 (en) * 2013-03-28 2015-11-12 Pharmacaribe, Llc Compositions, formulations and methods of bio-balancing the pH of sterile isotonic saline and hypertonic saline solutions
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
CN109475707A (zh) 2016-05-03 2019-03-15 精呼吸股份有限公司 用于输送流体到肺部系统的液滴输送装置及其使用方法
CN110799231B (zh) 2017-05-19 2022-08-02 精呼吸股份有限公司 干粉输送装置及其使用方法
CA3066408A1 (en) 2017-06-10 2018-12-13 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
US11738158B2 (en) 2017-10-04 2023-08-29 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device and methods of use
EP4344719A3 (de) 2017-10-17 2024-06-05 Pneuma Respiratory, Inc. Nasale arzneimittelabgabevorrichtung und verwendungsverfahren
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法
CN111647537B (zh) * 2020-06-18 2022-04-26 浙江工业大学 一种耐盐辣椒素降解菌、应用及餐厨垃圾处理方法
KR20240037245A (ko) 2021-06-22 2024-03-21 뉴마 레스퍼러토리 인코포레이티드 푸시 이젝션에 의한 액적 전달 장치

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572801A (en) * 1896-12-08 Telephone-exchange
US9126A (en) * 1852-07-13 Marcus r
US610824A (en) * 1898-09-13 Sleigh attachment for vehicles
US673739A (en) * 1900-09-19 1901-05-07 Frank B Stearns Driving mechanism for vehicles.
US775670A (en) * 1904-08-17 1904-11-22 Thomas F Whittelsey Air-brake safety device.
US946838A (en) * 1909-08-17 1910-01-18 George Dawson Tempering compound.
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4625022A (en) * 1981-02-02 1986-11-25 E. R. Squibb & Sons, Inc. Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4386034A (en) * 1981-02-02 1983-05-31 E. R. Squibb & Sons, Inc. Sulfamated amino acid amides
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4752469A (en) * 1984-01-09 1988-06-21 E. R. Squibb & Sons, Inc. Potentiators of beta-lactam antibiotics
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) * 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
WO1995019180A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
AU725733B2 (en) 1996-09-04 2000-10-19 Takara Bio Inc. Fungal antigens and process for producing the same
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en) 1998-06-16 1999-12-16 Serge Dea Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en) 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells and compositions
BR9916296A (pt) * 1998-12-17 2004-06-29 Pathogenesis Corp Método para tratamento de bronquite crÈnica severa (bronquiectase) com um antibiótico em forma de aerossol
WO2000073337A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. Polymer conjugates of hedgehog proteins and uses
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
HU229310B1 (en) * 1999-10-29 2013-10-28 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2002231244B2 (en) * 2000-12-27 2006-06-29 Gilead Sciences, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US6841096B2 (en) * 2001-10-08 2005-01-11 California Institute Of Technology Microfabricated lenses, methods of manufacture thereof, and applications therefor
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
CA2477979A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
EP1417958A1 (de) 2002-11-08 2004-05-12 Pari GmbH Feuchtgranulierungsverfahren
WO2004052333A1 (en) 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
ES2304078B2 (es) 2003-07-02 2009-09-16 Gilead Sciences Inc. Sal de aztreonam-l-lisina y metodos para la preparacion de la misma.
CN101951906A (zh) 2007-10-01 2011-01-19 吉里德科学公司 用于治疗肺病中的健康相关生命质量缺陷的吸入式氨曲南赖氨酸

Also Published As

Publication number Publication date
US20170296517A1 (en) 2017-10-19
NO2011001I2 (no) 2013-05-27
AU2002231244B2 (en) 2006-06-29
IL156596A0 (en) 2004-01-04
PT1353647E (pt) 2011-05-24
US9533000B2 (en) 2017-01-03
CY2011012I1 (el) 2014-04-09
JP2004516302A (ja) 2004-06-03
ATE502623T1 (de) 2011-04-15
ES2406405T3 (es) 2013-06-06
PT2301524E (pt) 2013-07-10
US20080050439A1 (en) 2008-02-28
LU91851I9 (de) 2019-01-03
ES2360692T3 (es) 2011-06-08
BE2011C029I2 (de) 2021-07-26
NL300492I2 (nl) 2017-11-02
BR0116757A (pt) 2003-11-04
IL221036A0 (en) 2012-08-30
CY2011012I2 (el) 2014-04-09
NO2011001I1 (no) 2011-02-07
LU91851I2 (fr) 2011-10-03
EP1353647B1 (de) 2011-03-23
JP4646489B2 (ja) 2011-03-09
EP2301524A1 (de) 2011-03-30
US6660249B2 (en) 2003-12-09
NO20032946L (no) 2003-08-26
BR0116757B1 (pt) 2014-02-04
CY1111571T1 (el) 2014-04-09
IL156596A (en) 2012-07-31
CA2708703A1 (en) 2002-07-04
US7208141B2 (en) 2007-04-24
DK1353647T3 (da) 2011-06-14
CA2708703C (en) 2012-12-04
WO2002051356A2 (en) 2002-07-04
NO20101377L (no) 2003-08-26
EP1353647A4 (de) 2007-05-09
CA2433280A1 (en) 2002-07-04
EP1353647A2 (de) 2003-10-22
US20030055034A1 (en) 2003-03-20
NO329643B1 (no) 2010-11-22
CA2433280C (en) 2010-09-21
US20050129623A1 (en) 2005-06-16
US20140037735A1 (en) 2014-02-06
NO20032946D0 (no) 2003-06-26
FR11C0030I2 (fr) 2012-03-16
DE122011100043I1 (de) 2011-12-15
DE60144291D1 (de) 2011-05-05
BRPI0116757B8 (pt) 2021-05-25
DK2301524T3 (da) 2013-07-15
WO2002051356A3 (en) 2002-10-31
EP2301524B1 (de) 2013-04-24
US20120093890A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
BE2011C029I2 (de)
CY1114621T1 (el) Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων
WO2011005354A3 (en) Gallium formulation for the treatment and prevention of infectious diseases
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
Tsuchiya et al. Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities
BR9303235A (pt) Compostos e processo para sua preparacao,formulacao farmaceutica,metodo para o combate de bacterias e metodo para o tratamento de infecoes bacterianas
WO2003097575A3 (en) Amino-functional chalcones
EP1057828A3 (de) Trovafloxacin enhaltende Suspensionen zur oralen Anwendung
EP1435357A3 (de) Neues Verfahren zur Herstellung von Vinyl-Pyrrolidin Cephalosporin Derivaten
CY1114144T1 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
AR040420A1 (es) Aztreonam inhalable para el tratamiento y la prevencion de infecciones bacterianas pulmonares
Sunagawa et al. Synthesis and biological properties of a new series of anti-MRSA β-lactams; 2-(thiazol-2′-ylthio) carbapenems
AU2002360218A1 (en) A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A Beta -LACTAM ANTIBIOTIC
GR1003520B (el) Μεθοδος χρησης ενωσεων φλουοροκινολονης εναντια σε νοσοκομειακα αρνητικα κατα gramμ παθογενων βακτηριδιων
Fuga et al. Bacterial flora in chronic suppurative otitis media
CA2468033A1 (en) A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent
HUP9802413A2 (hu) N-(Pirrolo-1-il)-piridin-amin-származékok alkalmazása görcsoldóként és görcsök kezelésére alkalmas gyógyszerkészítmény előállítására
Norrby Confronting the Challenge of Infection: The Role of Meropenem
AR054219A1 (es) Formulacion de lisinato de aztreonam inhalable para el tratamiento y la prevencion de infecciones pulmonares bacteriales